-
[show abstract]
[hide abstract]
ABSTRACT: As there is no standard treatment for advanced gastric cancer refractory to first-line chemotherapy, the feasibility of S-1 plus weekly docetaxel combined with concurrent radiotherapy was evaluated.
Ten patients were enrolled in this study. Patients were given S-1 at a daily dose of 40 mg/m(2) and docetaxel at a weekly dose of 20 mg/m(2) for 5 consecutive weeks, with concurrent radiotherapy (RT) amounting to a total irradiation dose of 45 Gy or 50.4 Gy.
Hematological toxicities were grade 3 or less except for anemia. Non-hematological toxicities were all grade 2 or less, apart from one grade 3 asthenia. There was one treatment-related death, resulting from melena, in a patient with a mechanical device in the radiation field. Planned treatment was delivered with relative dose intensity for S-1, docetaxel and RT as 94%, 98% and 97%, respectively. Median survival time of 297 days was obtained, with an objective response seen in 2 patients and symptom relief achieved in all patients.
S-1 plus weekly docetaxel combined with concurrent RT exhibited a tolerable toxicity profile with sufficient symptom palliation and prolonged survival in patients with advanced gastric cancer refractory to first-line chemotherapy.
Anticancer research 09/2009; 29(8):3385-91. · 1.73 Impact Factor
-
Yoshiaki Ohmura,
Kazumasa Fujitani, Hideya Yamasaki,
Motohiro Hirao,
Masayoshi Yasui,
Norikazu Masuda,
Masaki Kashiwazaki,
Masakazu Ikenaga,
Michihiko Miyazaki,
Koji Takami,
Hideyuki Mishima,
Shoji Nakamori,
Toshimasa Tsujinaka
[show abstract]
[hide abstract]
ABSTRACT: A 76-year-old man was admitted to our hospital complaining a weight loss and dysphagia. Gastro-intestinal fiberscopy (GIF) examination showed an early gastric cancer located at cardia. Because of his severe co-morbidities, such as unruptured intracranial aneurysm and idiopathic ventricular fibrillation, he was considered to be inoperable and only followed periodically by the GIF examination every half year. After 3 years since his first examination, the gastric cancer progressed to be T2 advanced gastric cancer. Chemo-radiation therapy (CRT) was administered for consecutive 5 weeks in the following fashion: weekly docetaxel (DOC) div 20 mg/m2 x 5 weeks, and RT 1.8 Gy/day x 5 days/week x 5 weeks. Although the CRT was completed on schedule, diarrhea of grade 3, serum creatinine elevation of grade 2, and esophageal candidiasis appeared during the therapy. A month later after the completion of CRT, the tumor disappeared thoroughly, leaving the tiny redness on the mucosa of cardia. Two months later after CRT, GIF examination reconfirmed the disappearance of the tumor. The patient has shown a clinical complete response (CR), suggesting the efficacy of CRT for inoperable gastric cancer.
Gan to kagaku ryoho. Cancer & chemotherapy 12/2007; 34(12):2147-9.
-
[show abstract]
[hide abstract]
ABSTRACT: The demand for minimally invasive therapies is increasing in the treatment of small peripheral non-small cell lung cancer (NSCLC).
Twelve patients with T1-2 N0 M0 peripheral NSCLC were treated by high-dose-rate brachytherapy with (192)Ir radioactive source.
A (192)Ir source was introduced into the tumors percutaneously in five patients (percutaneous brachytherapy) or transbronchially in seven patients (transbronchial brachytherapy). Whereas irradiation was performed with a single fraction of 20 Gy in percutaneous brachytherapy, it was hypofractionated from 5 x 5 Gy to 2 x 12.5 Gy in transbronchial brachytherapy. Complications were generally mild in all patients, although focal radiation pneumonitis was observed in most patients. Primary recurrence occurred in three patients, including one with a T2 tumor and one treated by brachytherapy as a salvage treatment for recurrence after conformal radiotherapy. When brachytherapy is evaluated as a primary treatment for T1 N0 M0 NSCLC, local control rate is 88.9% and estimated 5-year survival rate is between 60% and 70%.
Brachytherapy has a potential to be a method to treat peripheral T1 N0 M0 NSCLC.
Strahlentherapie und Onkologie 01/2007; 182(12):703-7. · 3.56 Impact Factor
